Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.
Can J Clin Pharmacol 16(1):e165-70 (2009) PMID 19221403
Sitagliptin is a highly selective dipeptidyl peptidase-4 inhibitor for the treatment of patients with type 2 diabetes. Sitagliptin is primarily excreted by renal elimination as unchanged drug, with only a small percentage (approximately 16%) undergoing hepatic metabolism.
Version: za2963e q8zac q8zbd q8zcb q8zd3 q8ze2 q8zf9 q8zgd